Literature DB >> 18698005

Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion.

Carlo Chizzolini1, Rachel Chicheportiche, Montserrat Alvarez, Casimir de Rham, Pascale Roux-Lombard, Sylvie Ferrari-Lacraz, Jean-Michel Dayer.   

Abstract

Microenvironment molecular cues direct T helper (Th) cell differentiation; however, Th17 fate determination is still imprecisely understood in humans. To assess the role of prostaglandin E(2) (PGE(2)) in Th expansion, we activated peripheral blood mononuclear cells by CD3 cross-linking. In the presence of exogenous PGE(2), peripheral blood mononuclear cells produced higher interleukin-17 (IL-17), C-C chemokine ligand 20 (CCL20)/macrophage inflammatory protein 3alpha (MIP-3alpha), CXC chemokine ligand 8 (CXCL8)/IL-8, and lower interferon-gamma and IL-22 levels than in control cultures. Exogenous PGE(2) and IL-23 synergized in inducing IL-17, whereas indomethacin and IL-23 blockade drastically reduced IL-17 but not interferon-gamma production. Furthermore, IL-1 but not tumor necrosis factor was absolutely required for IL-17 production. PGE(2) doubled the frequency of CD4+ T cells producing IL-17 and within the CD4+ subset enhanced C-C chemokine receptor 6 (CCR6) and CCR4 while decreasing CXC chemokine receptor 3 (CXCR3) expression. Furthermore, in CD4+ T-cell lines, the production of IL-17 segregated with the CCR6+ subset. In the presence of CCR6+ compared with CXCR3+ Th cells, monocytes/macrophages produced much higher levels of matrix metalloproteinase-1, -3, and -9 but similar levels of CXCL10 and IL-1beta. These results identify PGE(2) and IL-23 as participating in the expansion of CD4+ T cells endowed with high IL-17 production capacity, which in turn favors monocyte production of mediators important for host defense and tissue destruction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698005      PMCID: PMC2572797          DOI: 10.1182/blood-2008-05-155408

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia.

Authors:  Shean J Aujla; Yvonne R Chan; Mingquan Zheng; Mingjian Fei; David J Askew; Derek A Pociask; Todd A Reinhart; Florencia McAllister; Jennifer Edeal; Kristi Gaus; Shahid Husain; James L Kreindler; Patricia J Dubin; Joseph M Pilewski; Mike M Myerburg; Carol A Mason; Yoichiro Iwakura; Jay K Kolls
Journal:  Nat Med       Date:  2008-02-10       Impact factor: 53.440

2.  Distinct regulation of interleukin-17 in human T helper lymphocytes.

Authors:  Zhi Chen; Cristina M Tato; Linda Muul; Arian Laurence; John J O'Shea
Journal:  Arthritis Rheum       Date:  2007-09

3.  TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.

Authors:  Mandy J McGeachy; Kristian S Bak-Jensen; Yi Chen; Cristina M Tato; Wendy Blumenschein; Terrill McClanahan; Daniel J Cua
Journal:  Nat Immunol       Date:  2007-11-11       Impact factor: 25.606

4.  IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation.

Authors:  Hak-Ling Ma; Spencer Liang; Jing Li; Lee Napierata; Tom Brown; Stephen Benoit; Mayra Senices; Davinder Gill; Kyriaki Dunussi-Joannopoulos; Mary Collins; Cheryl Nickerson-Nutter; Lynette A Fouser; Deborah A Young
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

5.  Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells.

Authors:  Hyung W Lim; Jeeho Lee; Peter Hillsamer; Chang H Kim
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

6.  Human T cells that are able to produce IL-17 express the chemokine receptor CCR6.

Authors:  Satya P Singh; Hongwei H Zhang; John F Foley; Michael N Hedrick; Joshua M Farber
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

7.  Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells.

Authors:  Astrid J van Beelen; Zuzana Zelinkova; Esther W Taanman-Kueter; Femke J Muller; Daniel W Hommes; Sebastian A J Zaat; Martien L Kapsenberg; Esther C de Jong
Journal:  Immunity       Date:  2007-10-04       Impact factor: 31.745

8.  Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis.

Authors:  Amir F Sheibanie; Tanzilya Khayrullina; Fayez F Safadi; Doina Ganea
Journal:  Arthritis Rheum       Date:  2007-08

9.  Facilitation of Th1-mediated immune response by prostaglandin E receptor EP1.

Authors:  Miyako Nagamachi; Daiji Sakata; Kenji Kabashima; Tomoyuki Furuyashiki; Takahiko Murata; Eri Segi-Nishida; Kitipong Soontrapa; Toshiyuki Matsuoka; Yoshiki Miyachi; Shuh Narumiya
Journal:  J Exp Med       Date:  2007-10-29       Impact factor: 14.307

10.  Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model.

Authors:  Keiji Hirota; Hiroyuki Yoshitomi; Motomu Hashimoto; Shinji Maeda; Shin Teradaira; Naoshi Sugimoto; Tomoyuki Yamaguchi; Takashi Nomura; Hiromu Ito; Takashi Nakamura; Noriko Sakaguchi; Shimon Sakaguchi
Journal:  J Exp Med       Date:  2007-11-19       Impact factor: 14.307

View more
  95 in total

1.  Differential IL-21 signaling in APCs leads to disparate Th17 differentiation in diabetes-susceptible NOD and diabetes-resistant NOD.Idd3 mice.

Authors:  Sue M Liu; David H Lee; Jenna M Sullivan; Denise Chung; Anneli Jäger; Bennett O V Shum; Nora E Sarvetnick; Ana C Anderson; Vijay K Kuchroo
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

2.  Cyclooxygenase-1 orchestrates germinal center formation and antibody class-switch via regulation of IL-17.

Authors:  Victoria A Blaho; Matthew W Buczynski; Edward A Dennis; Charles R Brown
Journal:  J Immunol       Date:  2009-11-01       Impact factor: 5.422

3.  Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice.

Authors:  Jennifer L Ather; Karina Ckless; Rebecca Martin; Kathryn L Foley; Benjamin T Suratt; Jonathan E Boyson; Katherine A Fitzgerald; Richard A Flavell; Stephanie C Eisenbarth; Matthew E Poynter
Journal:  J Immunol       Date:  2011-05-27       Impact factor: 5.422

4.  Modulation of dendritic cell function by PGE2 and DHA: a framework for understanding the role of dendritic cells in neuroinflammation.

Authors:  Doina Ganea; Virginia Kocieda; Weimin Kong; Jui-Hung Yen
Journal:  Clin Lipidol       Date:  2011-06

5.  Prostaglandin E2 and IL-23 plus IL-1β differentially regulate the Th1/Th17 immune response of human CD161(+) CD4(+) memory T cells.

Authors:  Arthur Barrie; Anupriya Khare; Matthew Henkel; Yingze Zhang; M Michael Barmada; Richard Duerr; Anuradha Ray
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

Review 6.  Interleukin-1 function and role in rheumatic disease.

Authors:  Georg Schett; Jean-Michel Dayer; Bernhard Manger
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

7.  Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development.

Authors:  R Kesselring; A Thiel; R Pries; T Trenkle; B Wollenberg
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

Review 8.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

9.  Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration.

Authors:  Kristin Andreas; Thomas Häupl; Carsten Lübke; Jochen Ringe; Lars Morawietz; Anja Wachtel; Michael Sittinger; Christian Kaps
Journal:  Arthritis Res Ther       Date:  2009-02-03       Impact factor: 5.156

Review 10.  Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?

Authors:  Carlo Chizzolini; Jean-Michel Dayer; Pierre Miossec
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.